Study for advanced triple-negative breast cancer after prior treatments
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- Your breast cancer is confirmed as triple-negative, meaning ER-negative, PR-negative, and HER2-negative
- Your cancer is locally advanced (can’t have curative local treatment) or metastatic, and it has progressed after at least one prior treatment for advanced/metastatic disease
- You have at least one measurable tumor spot on scans (and that spot has not had radiotherapy)
- Your blood, liver, and kidney tests are strong enough for treatment (specific lab thresholds are required)
- You’re able to do daily activities fairly well (ECOG score 0–1) and are expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This study tests a new combination of drugs—cromolyn, TQB2102, and panpulimab—for women with triple negative breast cancer that has not responded to previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer and give you another treatment option.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This study tests a new way to choose treatment for advanced triple-negative breast cancer, based on a special analysis of your tumor. The goal is to find a treatment that works better for your specific cancer type.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.